Question-and-Answer Session
Operator
(Operator instructions) Your first question will come from Geoff Meacham from JP Morgan.
Harry – JP Morgan
This is Harry [ph] in for Geoff. Thanks for taking the question. Can you talk about the steps that you have put in place to drive back the fill rate back to the 90% range where it was before the economic downturn and do you think it is realistic that you can get back to the 90% range?
Gabriel Leung
Well the fill rate if you even look at last year is more in the 80s, the mid high 80s versus right now we are in the low to mid 80s range. And working with our partner, we have indeed initiated or in fact we have initiated an effort last year and continue to step it up to help with coinsurance and copay. But unfortunately because of the anti-kickback legislations we can only offer those programs to help with patients private pay patients and will not be able to assist with Medicare patients in that regard.
Harry – JP Morgan
Okay. And looking at your pipeline for OSI 906, the study in ACC, can you talk about what you see as the opportunity there and what your expectations are for enrollment in that study and completion of that study?
Colin Goddard
Clearly we recognized as I think everybody (inaudible) everybody for a disease that has got such a lower prevalence rate and maybe a 1000, 2000 patients in the US. This is a speed to market strategy which doesn't present important unmet medical need in that disease setting, but is actually in the broader context of the emerging 906 franchise much more important to establishing and validating the biology around IGF2 over expression and of course getting us out there in a speedy fashion. From the time to completion point of view, I mean obviously, we have just begun in the study. We'll see how enrolment goes. We have 45 sites targeted, we have a lot of interest from the community, feels like it is a 2012 type outcome for the study, and as we go into it and we will obviously keep you all updated as that progresses.
Harry – JP Morgan
Okay, thanks.
Operator
And your next question will come from Howard Liang with Leerink Swann.
Howard Liang – Leerink Swann
Thanks very much. Can you just talk a little about your interactions with the FDA regarding the SATURN approval, it sounds like you're pretty confident of approval? And secondly whether do you see an impact of the maintenance approval on your ability to talk to physicians about the EGFR testing and use of Tarceva in EGFR mutation patients?
- To read the full transcript on Seeking Alpha, click here »
